Francis J. Giles

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

Hagop M. Kantarjian, Francis J. Giles, Lydia Wunderle et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

Michael J. Keating, Susan O’Brien, Maher Albitar et al. · Journal of Clinical Oncology · 2005 · 951 citations · Full text

Medicine, Immunology, Oncology +14

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies

Jean‐Pierre J. Issa, Guillermo Garcia‐Manero, Francis J. Giles et al. · Blood · 2003 · 817 citations

Medicine, Oncology, Pharmacology +14

Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

Hagop M. Kantarjian, Susan O’Brien, Terry L. Smith et al. · Journal of Clinical Oncology · 2000 · 795 citations

Medicine, Hematology, Oncology +15

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Hagop M. Kantarjian, Francis J. Giles, Norbert Gattermann et al. · Blood · 2007 · 745 citations · Full text

Medicine, Oncology, Pharmacology +9